Cytokinetics Announces Data From REDWOOD-HCM OLE and : compa

Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class,...

Related Keywords

Oregon , United States , Fadyi Malik , Ahmad Masri , Cytokinetics Incorporated Nasdaq , International Congress , School Of Medicine , Division Of Cardiovascular Medicine , European Society Of Cardiology , Oregon Health Science University , Research Development , Six Months , Aficamten Show Significant , Sustained Reductions , Functional Class , Low Blood Pressure Have Increased Treatment , Randomized Evaluation , Dosing With , Obstructive Outflow Disease , Label Extension , Global Approach , Heart Failure , Late Breaking Science Sessions , European Society , European Heart , Cytokinetic Executive Vice President , First Long Term Data , Open Label Extension , Assistant Professor , Cardiovascular Medicine , Oregon Health , Science University , Nasdaq Cytk , Cytokinetics , Ncorporated , Cytk , Biotechnology ,